SEPREHVIR®

VIRTTU's lead product SEPREHVIR® (HSV1716) is a "first in class" engineered oncolytic herpes simplex virus designed to selectively target and destroy cancerous cells whilst leaving healthy cells unharmed.

We have completed Phase I clinical trials with HSV1716 in 47 patients with glioma (in 3 trials), in 5 patients with melanoma, and in 20 patients with squamous cell carcinoma of the head and neck.

There has been no observed toxicity attributable to the use of HSV1716 in any of these clinical studies. Our intention is to follow through with an efficacy study of SEPREHVIR® (HSV1716) in a randomised controlled clinical study in newly diagnosed glioblastoma multiforme.

Further clinical studies are planned as part of our goal to identify effective treatments for a range of other cancers including hepatocelllular carcinoma and mesothelioma.

In May 2010 the first clinical study in the US commenced at Cincinnati Children's Hospital Medical Center. The study is investigating the use of HSV1716 in paediatric/young adults with non-central nervous system tumours including sarcomas or neuroblastomas.

Products in clinical development

ProductIndicationResearch &
Pre-clinical
Phase IPhase IIPhase IIIStatus

SEPREHVIR®

(HSV1716)

Malignant brain tumours Completed 3x Ph I Completed In preparation  

Orphan Drug Status (EMA) Study in primary GBM planned

SEPREHVIR®

 (HSV1716)

Squamous cell carcinoma of head and neck Completed Ph I Completed     Phase I trial completed

SEPREHVIR®

 (HSV1716)

Malignant melanoma Completed Ph I Completed     Phase I trial completed

SEPREHVIR®

 (HSV1716)

Hepatocellular carcinoma Completed  In Preparation     Due to commence Q4 2011

SEPREHVIR®

 (HSV1716)

Malignant pleural mesothelioma Completed  In Preparation     Due to commence Q4 2011

SEPREHVIR®

 (HSV1716)

Paediatric and young adults with Non-CNS solid tumours (eg neuroblastoma or sarcoma) Completed Ongoing    

Recruiting at Cincinnati Children's Hospital Medical Center